12-Dec-2019

Dr James Garner discusses GBM AGILE study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.